Published Apr 20, 2026, 5:49 PM ET · Updated 7 months ago · 1 source
Compass Pathways CEO on Trump's Order to Expand Psychedelics Research
bloomberg
·
Original Report
INFERY
Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its highest intraday level since July 2023. The new order directs the US Food and Drug Administration to